Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis strongly associated with inflammatory bowel disease (IBD). This narrative review summarizes current knowledge on the epidemiology, clinical features, proposed mechanisms, and treatment of PG in patients with IBD. In addition to population-based, large cohort, and mechanistic studies, we reviewed 115 published case reports and case series describing patients with PG and IBD and synthesized demographic, clinical, and therapeutic trends. Most patients developed PG after an IBD diagnosis, with smaller proportions presenting simultaneously or before an IBD diagnosis. PG in IBD patients typically affects middle-aged adults and has a female predominance. Clinical features are heterogeneous, which complicates recognition and timely diagnosis. Treatment responses are also highly variable. Corticosteroids and immunosuppressants are commonly used as first-line therapies, but many patients require sequential or combined regimens. Biologics are increasingly used, reflecting efforts to target shared inflammatory pathways between PG and IBD; however, treatment approaches remain highly individualized. Mechanistic and genetic studies implicate Th17/Th1 immune dysregulation, IL-1β/IL-36 signaling, and gut-skin immune crosstalk. There is a critical need for longitudinal, controlled studies to clarify pathogenesis, predict outcomes, and guide evidence-based, standardized treatment approaches in this complex patient population.
Pyoderma gangrenosum (PG) is a rare dermatologic disease resulting in chronic, painful ulcerations, most commonly on the lower extremity. Pruritus is a common symptom in many dermatologic conditions but has not been thoroughly evaluated in patients with PG. We sought to characterize the prevalence, severity, and impact on QOL of lesional pruritus in patients with PG. Data were obtained from the "Pyoderma Gangrenosum Study" (IRB#16753) at Oregon Health and Science University. Standardized outcome data were prospectively collected during clinical encounters from December 2019 to May 2024. Inclusion criteria were adults who presented for at least 2 clinical visits and a PARACELSUS score ≥10. We analyzed data from 136 patients with 178 ulcers. At baseline, 69% of the patients reported moderate pruritus with a mean severity of 3.3 (0-10 scale, 95% confidence interval = 2.9-3.8), which decreased with healing (from 3.7 to 2.6). QOL scores (Skindex-Mini, Wound-QoL) improved in parallel with healing. Higher pruritus severity was associated with younger age and inflammatory arthritis, whereas analgesic use and systemic therapies showed no consistent associations. In summary, our findings suggest that lesional pruritus is a common symptom among patients with PG and significantly affects their QOL. These findings support routine assessment and antipruritic interventions in the management of PG.